SERA earnings analysis
What we found in SERA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Sera Prognostics delivered $30,000 of second-quarter revenue, up sharply from the prior quarter and prior year but below the $66,000 consensus estimate, while diluted EPS of negative $0.18 missed the negative $0.16 estimate. Operating expenses of $10.0 million and a $9.1 million net loss indicate continued substantial cash consumption, although management cites approximately $80.3 million of liquidity expected to fund operations through commercialization milestones through 2029. Payer engagement, Illinois coverage for approximately 50,000 annual Medicaid births and positive PRIME clinical findings are constructive, but concentration in the PreTRM test, reimbursement uncertainty and the need for additional capital remain significant risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Rebounded Sequentially and Year Over Year
- Second-quarter revenue was $30,000, up $16,000, or 114%, from $14,000 in Q1 2026 and up $13,000, or 76%, from $17,000 in Q2 2025.
- Payer Engagement and Coverage Advanced
- Commercial traction expanded to more than 20 payer opportunities, while Illinois coverage was cited for approximately 50,000 annual Medicaid births.
- Clinical Evidence Continued to Build
- PRIME-reported clinical results indicated reductions in NICU admissions and neonatal morbidity, supporting the potential clinical value of the PreTRM test; the filing did not quantify the reductions.
- Liquidity Runway Extends Through 2029
- Management reported approximately $80.3 million of cash, cash equivalents and available-for-sale securities, expected to fund operations through commercialization milestones through 2029.
- Disclosure Controls Remained Effective
- Disclosure controls and procedures were assessed as effective as of June 30, 2026, and the company reported no material changes in internal control over financial reporting during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Losses and Operating Costs Remain Elevated
- Diluted EPS was negative $0.18, compared with negative $0.17 in Q1 2026 and negative $0.16 in Q2 2025. Operating expenses increased to $10.0 million and the net loss was $9.1 million for the quarter.
- Additional Capital May Be Required
- The company reported a six-month 2026 net loss of $17.5 million versus $16.2 million in the comparable 2025 period and an accumulated deficit of $329.3 million as of June 30, 2026. Management states it expects to continue incurring losses for the foreseeable future and expects to need additional capital.
- PreTRM and Customer Concentration
- Substantially all revenue is generated by the PreTRM test, and the company expects to rely on a limited number of direct customers in the near future. The filing specifically identifies Elevance Health as a significant potential customer, increasing product and customer concentration risk.
- Interest-Rate and Liquidity Exposure
- A hypothetical 100-basis-point increase in interest rates would have reduced the market value of available-for-sale debt securities by $0.5 million as of June 30, 2026. Higher rates could also increase borrowing costs and restrict access to additional financing.
- Tariff and Supply-Chain Headwinds
- The filing highlights new trade-policy uncertainty, including a 10% global tariff imposed under a separate executive order after certain prior tariffs were invalidated in February 2026. Tariffs could increase laboratory, supply-chain and clinical-trial costs.
- Reporting Transition and Potential Dilution
- The company may remain an emerging growth company until December 31, 2026, and its reduced reporting requirements could make the stock less attractive to some investors. The filing also disclosed a Rule 10b5-1 plan covering up to 334,684 shares plus shares sold for RSU tax withholding.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.18
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management stated that approximately $80.3 million of cash, cash equivalents and available-for-sale securities is expected to fund operations through commercialization milestones through 2029.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 6, 2026
- Sera Prognostics reported disappointing financial results for Q4 2025, with revenue of $10 million and a diluted EPS of -$0.16, both down from the previous quarter and year. Despite an intention to focus on…
- 10-K · March 18, 2026
- Sera positions itself around a proprietary proteomics/bioinformatics platform and a clinically validated PreTRM test, highlighting PRIME/AVERT trial evidence (e.g., PRIME: 20% reduction in NICU admissions; 56% reduction…
- 10-Q · August 6, 2025
- Sera reported Q2 revenue of $17,000 and GAAP diluted loss per share of $(0.16), modestly improved from $(0.25) in Q2 2024. The quarter shows materially negative gross margin (−141.2%) and very large operating loss…
- 10-Q · November 6, 2024
- Sera reported Q3 revenue of $29,000 and GAAP net loss per share of $(0.24). Gross margin expanded to 55.2% versus a loss in the prior-year quarter, but operating loss widened to $8.862 million on only $29,000 of…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SERA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever